solhkhabar | Peace International News Agency Peace International News Agency , Peace News , International Agency News of Peace
Talking to IRNA, Mostafa Qane'ei added that two issues matters in buying Pfizer vaccine; one is its price and the other the temperature minus 70 it should be kept and transported to farthest points across the country.
While Iran is able to buy a vaccine whose cold chain is compatible with the country's infrastructure and its price is more appropriate and is produced by a reputable company, there is no reason to buy a vaccine that it completely lacks the infrastructure needed for its transport, he said.
Iran will not replace Pfizer vaccine with those of Russia and China, he said, noting that Europe now also has a vaccine, and AstraZeneca announced that it will produce its own vaccine as many as three billion doses, and in any case, this vaccine does not require a cold chain, and it is also a valid production.
It is a vaccine proposed by the University of Oxford and AstraZeneca has finalized its production, he said, noting that this vaccine, compared to Pfizer vaccine has no problem both in terms of price and amount of production and transmission chain; Therefore, there is not only one option in buying coronavirus vaccine.
As to the efficiency of the European vaccine produced by AstraZeneca, Qane'ei said that according to the documents published it is effective up to 95%.
8072**1424
Follow us on Twitter @IrnaEnglish
IRNA English